Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyripyropene A is a fungal-derived small molecule that potently and selectively inhibits acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2), an enzyme involved in the esterification of cholesterol in the intestine and liver. It is highly selective for ACAT2 over ACAT1 (IC50 ~70 nM for ACAT2, >80 μM for ACAT1), and in animal models, oral administration reduces intestinal cholesterol absorption, plasma cholesterol, LDL and VLDL cholesterol, hepatic cholesterol, and atherosclerotic lesions. Pyripyropene A has been used as a lead compound for the development of anti-atherosclerotic agents but is primarily a tool compound for research use in ACAT2 biology and cholesterol metabolism studies[1][3][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyripyropene A.